Login to Your Account

Pfizer Continues Buyout Trend, Paying $1.9B To Take Vicuron

By Randall Osborne

Friday, June 17, 2005
Vicuron Pharmaceuticals Inc.'s stock value skyrocketed on news that the firm has become the latest takeover target for Pfizer Inc., which made public its plan to buy the company for $29.10 per share, or about $1.9 billion - a 74-whopping-percent premium over the firm's 90-day average closing price and 21 percent higher than the highest historical closing price. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription